Form 4: Trevi Therapeutics Director Anne VanLent Reports Stock Option Grant

Director Anne VanLent reports the acquisition of 30,000 nonstatutory stock options in Trevi Therapeutics, Inc.

Summary

• On June 14, 2024, Anne VanLent, a director of Trevi Therapeutics, Inc., filed a Form 4 with the SEC.
• The form reports a transaction that occurred on June 13, 2024, where Ms. VanLent acquired 30,000 nonstatutory stock options.
• The exercise price of these options is $2.77.
• The options vest fully on the earlier of the first anniversary of the grant date (June 13, 2025) or the date of the next annual meeting of stockholders following the grant date, contingent upon continued service to the company.
• Following the reported transaction, Ms. VanLent directly owns 30,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their director compensation plans.
• The vesting schedules and exercise prices are typically structured to incentivize long-term value creation and align with industry norms.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing value creation.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates